PharmaTher Holdings Ltd. (
CSE.PHRM) – a psychedelics biotech company focused on the development and commercialization of specialty ketamine pharmaceuticals for mental health, neurological, and pain disorders – announce positive topline results from the dose-finding and tolerability clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
The study results are adequate to give an effect size in powering a Phase 3 clinical study, which is expected to bridge the design with increased treatment duration relative to the Company’s Phase 2 clinical study.
Click
here for full press release.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.